Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis.
Department of Medicine.
Amara S
AS
Hussain
Department of Medicine.
Parameswaran
P
Hari
Medical College of Wisconsin, Institute of Health and Society, Milwaukee, Wisconsin.
Ruta
R
Brazauskas
Department of Medicine.
Carlos
C
Arce-Lara
Department of Medicine.
Marcelo
M
Pasquini
Department of Medicine.
Mehdi
M
Hamadani
Department of Medicine.
Anita
A
D'Souza
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D000069286:Bortezomib / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D011379:Prognosis; D012720:Severity of Illness Index; D020107:Troponin T / Q000097:blood
D000970:Antineoplastic Agents; D015415:Biomarkers; D010446:Peptide Fragments; D020107:Troponin T; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide; D003404:Creatinine